The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
1
Edited News | OHCHR , UNOG
Israeli military operations in Lebanon continue to kill and injure civilians, and destroy civilian infrastructure, raising concerns regarding the protection of civilians, the UN Human Rights Office warned today.
1
1
1
Edited News | IOM , UNWOMEN , UNDP
Sudan: Aid teams report massive displacement after latest Darfur atrocity; women’s bodies ‘turned into battlegrounds’
In Sudan’s North Darfur, tens of thousands of people have fled a displacement camp following the massacre of civilians and aid workers as the country enters the third year of a conflict marked by horrific levels of sexual violence, UN humanitarians said on Tuesday.
1
1
1
Edited News | ITC
Global trade could shrink by three per cent as a result of the United States’ new tariff measures which in the longer term could reshape and boost as-yet untapped regional commercial links, a top UN economist confirmed on Friday.
1
1
1
Edited News | OHCHR , UNOG
Warring parties in Sudan are overseeing a wholesale assault on human rights amid global inaction, the UN Human Rights Office said on Friday, as the conflict is about to enter its third year.
1
1
1
Edited News | OHCHR , UNOG
The UN Human Rights Office on Friday said Israel’s increasing issuance of so-called “evacuation orders” for Palestinians in Gaza have resulted in their forcible transfer.
1
1
1
Edited News | OCHA , OHCHR , UNHCR , UNWOMEN , WFP , WHO
Two years of war in Sudan have created epic suffering, aid agencies say
Two years since Sudan’s brutal conflict began, UN agencies warned that famine is spreading and civilians of all ages continue to suffer shocking abuse, including rape and gang rape.
1
1
Edited News | UNMAS
In Gaza, ongoing Israeli military operations and the aid blockade have continued to add to daily fears and hardships confronting those in the devastated enclave, the UN Mine Action Service, UNMAS, said on Wednesday.
1
1
1
Edited News | UNDP
Dangers grow for Myanmar earthquake survivors, health system 'overwhelmed' - UNDP
In earthquake-shattered central Myanmar people are sleeping in the streets in fear of buildings collapsing, facing early monsoon rains and the risk of waterborne diseases, the UN Development Programme warned on Tuesday.
1
1
1
Edited News | ICRC , OHCHR , UNHCR
Myanmar’s military has continued to launch airstrikes and other attacks against opposition forces in the devastated country, one week since a 7.7 magnitude earthquake struck and despite announcing a ceasefire, UN human rights chief Volker Türk said on Friday.
1
1
1
Edited News | OHCHR
UN Deputy High Commissioner for Human Rights Nada Al-Nashif on Tuesday presented a report on the human rights situation in the Democratic Republic of Congo, detailing the continued violations of human rights as a result of the offensive launched by the Rwandan-backed M23 in eastern DRC.
1
1
1
Edited News | OCHA , UNICEF , IFRC
UN humanitarians and partners on Tuesday expressed deep shock at the killing of 15 colleagues on duty in southern Gaza whose remains were recovered from a shallow grave after a week-long rescue operation, noting that one worker is still missing.
1
1
1
Edited News | UNICEF , OCHA , WHO , UNHCR
Myanmar earthquake latest: window for lifesaving support is closing, say UN humanitarians
As the death toll continues to rise in earthquake-struck Myanmar, UN humanitarians have been rushing to support severely deprived and traumatized victims, warning that the window for lifesaving response is closing.